One stone with two birds: Phytic acid-capped platinum nanoparticles for targeted combination therapy of bone tumors

Biomaterials. 2019 Feb:194:130-138. doi: 10.1016/j.biomaterials.2018.12.024. Epub 2018 Dec 21.

Abstract

Targeted drug delivery to malignant bone lesions remains a challenging task in the treatment of bone tumors. In this article, we reported a naturally occurring phytic acid (PA) with both bone-targeting capability and anticancer activity. The PA-capped platinum nanoparticles showed high affinity to hydroxyapatite in vitro and in vivo, and maintained both the inherent anticancer ability of PA and photothermal effect of platinum nanoparticles. PA-capped nanoparticles displayed a 4-fold higher accumulation in the osteolytic lesions than sodium citrate-templated ones, and efficiently inhibited bone tumor growth and the tumor associated-osteolysis upon exposure to a near-infrared light. This study provides a novel and efficient strategy to prepare bone-targeted nanoparticles with inherent anticancer activity for combination therapy of malignant bone tumors.

Keywords: Bone targeting; Combination therapy; Inherent anticancer activity; Photothermal therapy; Phytic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / therapy*
  • Cell Line, Tumor
  • Combined Modality Therapy / methods
  • Drug Delivery Systems / methods
  • Humans
  • Hyperthermia, Induced / methods
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NIH 3T3 Cells
  • Nanoparticles / therapeutic use*
  • Phytic Acid / therapeutic use*
  • Platinum / therapeutic use*

Substances

  • Antineoplastic Agents
  • Platinum
  • Phytic Acid